{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:04:23Z","timestamp":1783533863936,"version":"3.55.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2016,4,21]],"date-time":"2016-04-21T00:00:00Z","timestamp":1461196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Heart failure (HF) and chronic obstructive pulmonary disease (COPD) frequently co-exist, and each is a major public health issue. In a large cohort of hospitalized HF patients, we evaluated: (i) the impact of COPD on clinical outcomes; (ii) whether outcomes and treatments changed from 2002 to 2009; and (iii) the relationship between outcomes and treatments focusing on beta-blockers (BBs) and bronchodilators (BDs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>From linkable Lombardy administrative health databases, we selected individuals with a discharge diagnosis of HF with or without concomitant COPD (HF yesCOPD and HF noCOPD) in 2002 and 2009. Patients were followed up for 4 years. Outcomes were total mortality, first readmission for HF, and their combination. Unadjusted and adjusted Cox proportional models and competing risk analyses were used. We identified 11 274 patients with HF noCOPD and 2837 with HF yesCOPD. HF yesCOPD patients in 2002 and 2009 had a 20% higher risk of the outcomes. From 2002 to 2009, BB and BD prescriptions increased significantly. In HF noCOPD patients, risks for mortality [adjusted hazard ratio (HR) 0.91, 95% confidence interval (CI) 0.86\u20130.97], first HF readmission (HR 0.79, 95% CI 0.74\u20130.85), and the combined endpoint (HR 0.88, 95% CI 0.84\u20130.92) declined (all P &amp;lt; 0.003) while in HF yesCOPD only the risk for first HF readmission dropped (HR 0.86, 95% CI 0.76\u20130.97; P = 0.018). BBs were associated with significantly lower mortality in both groups, but with a higher risk for first HF readmission in HF noCOPD. Outcomes did not significantly differ in HF yesCOPD treated or not with BDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The prognosis of patients hospitalized for HF, either with or without COPD, seemed to improve between 2002 and 2009, with possibly better survival of those on BBs. Because of residual confounding in observational studies, a randomized controlled trial should be considered to confirm these results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.519","type":"journal-article","created":{"date-parts":[[2016,4,21]],"date-time":"2016-04-21T09:04:17Z","timestamp":1461229457000},"page":"840-848","source":"Crossref","is-referenced-by-count":25,"title":["Outcomes in Patients Hospitalized for Heart Failure and Chronic Obstructive Pulmonary Disease: Differences in Clinical Profile and Treatment between 2002 and 2009"],"prefix":"10.1093","volume":"18","author":[{"given":"Lidia","family":"Staszewsky","sequence":"first","affiliation":[{"name":"Laboratory of Cardiovascular Clinical Pharmacology, IRCCS - Istituto di Ricerche Farmacologiche \u2018Mario Negri\u2019 , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cortesi","sequence":"additional","affiliation":[{"name":"Laboratory of General Practice Research, IRCCS - Istituto di Ricerche Farmacologiche \u2018Mario Negri\u2019 , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Tettamanti","sequence":"additional","affiliation":[{"name":"Laboratory of Geriatric Epidemiology, IRCCS - Istituto di Ricerche Farmacologiche \u2018Mario Negri\u2019 , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrio Andrea","family":"Dal Bo","sequence":"additional","affiliation":[{"name":"Unit of Internal and Respiratory Medicine, Fatebenefratelli e Oftalmico Hospital , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Fortino","sequence":"additional","affiliation":[{"name":"Regional Health Ministry, Lombardy Region , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Bortolotti","sequence":"additional","affiliation":[{"name":"Regional Health Ministry, Lombardy Region , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Merlino","sequence":"additional","affiliation":[{"name":"Regional Health Ministry, Lombardy Region , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Latini","sequence":"additional","affiliation":[{"name":"Laboratory of Cardiovascular Clinical Pharmacology, IRCCS - Istituto di Ricerche Farmacologiche \u2018Mario Negri\u2019 , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carla","family":"Roncaglioni","sequence":"additional","affiliation":[{"name":"Laboratory of General Practice Research, IRCCS - Istituto di Ricerche Farmacologiche \u2018Mario Negri\u2019 , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Baviera","sequence":"additional","affiliation":[{"name":"Laboratory of General Practice Research, IRCCS - Istituto di Ricerche Farmacologiche \u2018Mario Negri\u2019 , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,4,21]]},"reference":[{"key":"2026011721152864100_ejhf519-bib-0001"},{"key":"2026011721152864100_ejhf519-bib-0002","first-page":"e29","article-title":"American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics\u20142015 update: a report from the American Heart Association","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"key":"2026011721152864100_ejhf519-bib-0003","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ejheart.2006.01.010","article-title":"Heart failure and chronic obstructive pulmonary disease: an ignored combination?","volume":"8","author":"Rutten","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"2026011721152864100_ejhf519-bib-0004","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1365-2796.2008.01975.x","article-title":"Chronic obstructivepulmonary disease in patients admitted with heart failure","volume":"264","author":"Iversen","year":"2008","journal-title":"J Intern Med"},{"key":"2026011721152864100_ejhf519-bib-0005","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1093\/eurheartj\/eht192","article-title":"Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services","volume":"34","author":"Hawkins","year":"2013","journal-title":"Eur Heart J"},{"key":"2026011721152864100_ejhf519-bib-0006","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jacc.2006.08.046","article-title":"Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure","volume":"49","author":"Le Jemtel","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026011721152864100_ejhf519-bib-0007","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0954-6111(03)00168-9","article-title":"Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis","volume":"97","author":"Salpeter","year":"2003","journal-title":"Respir Med"},{"key":"2026011721152864100_ejhf519-bib-0008","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/eurjhf\/hfs009","article-title":"Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF","volume":"14","author":"Mentz","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026011721152864100_ejhf519-bib-0009","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1378\/chest.14-0607","article-title":"Impact of COPD on the mortality and treatment of patients hospitalized with acute decompensate heart failure: the Worcester Heart Failure Study","volume":"147","author":"Fisher","year":"2015","journal-title":"Chest"},{"key":"2026011721152864100_ejhf519-bib-0010","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0002-9343(02)01346-3","article-title":"The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure","volume":"113","author":"Sin","year":"2002","journal-title":"Am J Med"},{"key":"2026011721152864100_ejhf519-bib-0011","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.cardfail.2007.07.012","article-title":"Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial","volume":"13","author":"Staszewsky","year":"2007","journal-title":"J Card Fail"},{"key":"2026011721152864100_ejhf519-bib-0012","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ejheart.2007.06.004","article-title":"The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure","volume":"9","author":"Macchia","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"2026011721152864100_ejhf519-bib-0013","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/eurjhf\/hfp001","article-title":"Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)","volume":"11","author":"Hawkins","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026011721152864100_ejhf519-bib-0014","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.cardfail.2012.04.010","article-title":"The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial","volume":"18","author":"Mentz","year":"2012","journal-title":"J Card Fail"},{"key":"2026011721152864100_ejhf519-bib-0015","first-page":"e240","article-title":"American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines"},{"key":"2026011721152864100_ejhf519-bib-0016","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","article-title":"ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026011721152864100_ejhf519-bib-0017","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1378\/chest.123.6.1964","article-title":"Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction","volume":"123","author":"Au","year":"2003","journal-title":"Chest"},{"key":"2026011721152864100_ejhf519-bib-0018","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/eurjhf\/hfq040","article-title":"Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme","volume":"12","author":"Hawkins","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026011721152864100_ejhf519-bib-0019","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ejhf.471","article-title":"The real-world evidence of heart failure: findings from 41\u2009413 patients of the ARNO database","volume":"18","author":"Maggioni","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721152864100_ejhf519-bib-0020","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12872-015-0127-9","article-title":"Factors associated with 30-day readmission of patients with heart failure from a Japanese administrative database","volume":"15","author":"Aizawa","year":"2015","journal-title":"BMC Cardiovasc Disord"},{"key":"2026011721152864100_ejhf519-bib-0021","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/eurjhf\/hfp160","article-title":"Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland","volume":"12","author":"Hawkins","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026011721152864100_ejhf519-bib-0022","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S2213-2600(15)00157-5","article-title":"Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data","volume":"3","author":"Soriano","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2026011721152864100_ejhf519-bib-0023","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/CIRCHEARTFAILURE.114.001360","article-title":"Effect of fixed-dose combination of isosorbidedinitrate and hydralazine on all hospitalizations and on 30-day readmission rates in patients with heart failure: results from the African-American Heart Failure Trial","volume":"7","author":"Anand","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026011721152864100_ejhf519-bib-0024","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Heart Failure Association of the ESC. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011721152864100_ejhf519-bib-0025","doi-asserted-by":"crossref","first-page":"f596","DOI":"10.1136\/bmj.f55","article-title":"Benefits of \u03b2 blockers in patients with heart failure and reduced ejection fraction: network meta-analysis","volume":"346","author":"Chatterjee","year":"2013","journal-title":"BMJ"},{"key":"2026011721152864100_ejhf519-bib-0026","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.jacc.2011.02.020","article-title":"Heart failure and chronic obstructive pulmonary disease: the quandary of beta-blockers and beta-agonists","volume":"57","author":"Hawkins","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026011721152864100_ejhf519-bib-0027","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/eurjhf\/hfp066","article-title":"Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial","volume":"11","author":"Hawkins","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026011721152864100_ejhf519-bib-0028","doi-asserted-by":"crossref","first-page":"d2549","DOI":"10.1136\/bmj.d2549","article-title":"Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study","volume":"342","author":"Short","year":"2011","journal-title":"BMJ"},{"key":"2026011721152864100_ejhf519-bib-0029","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/archinternmed.2010.112","article-title":"Beta-blockers may reduce mortality and risk of exacerbations of patients with chronic obstructive pulmonary disease","volume":"170","author":"Rutten","journal-title":"Arch Intern Med"},{"key":"2026011721152864100_ejhf519-bib-0030","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ijcard.2014.03.005","article-title":"Beta-blockers in older patients with heart failure and preserved ejection fraction: class, dosage, and outcomes","volume":"173","author":"Patel","year":"2014","journal-title":"Int J Cardiol"},{"key":"2026011721152864100_ejhf519-bib-0031","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jchf.2012.09.002","article-title":"Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis","volume":"1","author":"Rienstra","year":"2013","journal-title":"JACC Heart Fail"},{"key":"2026011721152864100_ejhf519-bib-0032","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(14)61373-8","article-title":"Efficacy of \u03b2 blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis","volume":"384","author":"Kotecha","year":"2014","journal-title":"Lancet"},{"key":"2026011721152864100_ejhf519-bib-0033","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","article-title":"Changes in diabetes-related complications in the United States, 1990\u20132010","volume":"370","author":"Gregg","year":"2014","journal-title":"N Engl J Med"},{"key":"2026011721152864100_ejhf519-bib-0034","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.2337\/dc12-2197","article-title":"Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications","volume":"36","author":"Haughey","year":"2013","journal-title":"Diabetes Care"},{"key":"2026011721152864100_ejhf519-bib-0035","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.rmed.2011.01.012","article-title":"Validity and under recording of diagnosis of COPD in the Danish National Patient Registry","volume":"105","author":"Thomsen","year":"2011","journal-title":"Respir Med"},{"key":"2026011721152864100_ejhf519-bib-0036","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/15412550903140865","article-title":"Identifying individuals with physician diagnosed COPD in health administrative databases","volume":"6","author":"Gershon","year":"2009","journal-title":"COPD"},{"key":"2026011721152864100_ejhf519-bib-0037","first-page":"e5","article-title":"Validity of chronic obstructive pulmonary disease diagnosis in a large administrative database","volume":"19","author":"Lacasse","year":"2012","journal-title":"Can Respir J"},{"key":"2026011721152864100_ejhf519-bib-0038","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1016\/j.ijcard.2012.12.083","article-title":"Airway obstruction in systolic heart failure\u2014COPD or congestion?","volume":"168","author":"Brenner","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026011721152864100_ejhf519-bib-0039","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/heartjnl-2012-302313","article-title":"Specialist clinics for reducing emergency admissions in patients with heart failure: a systematic review and meta-analysis of randomised controlled trials","volume":"99","author":"Thomas","year":"2013","journal-title":"Heart"},{"key":"2026011721152864100_ejhf519-bib-0040","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ejhf.30","article-title":"Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey","volume":"16","author":"Van Deursen","year":"2014","journal-title":"Eur J Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.519","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/18\/7\/840\/66382748\/eurjhf_18_7_840.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/18\/7\/840\/66382748\/eurjhf_18_7_840.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:16:05Z","timestamp":1768702565000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/18\/7\/840\/8423291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,21]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,4,21]]},"published-print":{"date-parts":[[2016,7,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.519","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,7]]},"published":{"date-parts":[[2016,4,21]]}}}